The U.S. Supreme Court said April 21 it would block a lower court’s restrictions on an abortion pill, leaving the drug on the market while litigation over the drug proceeds.
Supreme Court blocks lower court’s restrictions on abortion pill, leaving drug on the market during litigation
FDA decision on medical abortion puts women’s lives, health at risk, says bishops’ pro-life chair
By no longer requiring the abortion drug mifepristone to be picked up in person, the U.S. Food and Drug Administration is “merely succumbing to the abortion industry’s pressure to loosen safety standards,” instead of protecting the lives and health of mothers and children as it should do, he said.
FDA criticized for lifting in-person requirement to receive abortion drug
The decision by the acting commissioner of the U.S. Food and Drug Administration to suspend enforcement of the agency’s in-person prescribing requirement for the abortion drug endangers women’s health and possibly their lives, pro-life leaders said.